We review advanced thyroid cancer (TC) etiology and signaling pathway mutations.
We review the mechanism of action and role of tyrosine kinase inhibitors (TKIs).
Lenvatinib, a multitargeted TKI, has broad antitumor and antiangiogenic activity.
We review phase III radioactive iodine-refractory differentiated TC results.
Lenvatinib shows superior progression-free survival and overall response rate.